YourChoice
8 known investors
YourChoice Therapeutics is developing YCT-529, a non-hormonal oral contraceptive for men currently in Phase 2 clinical trials. The company targets male contraceptive users seeking alternatives to condoms or vasectomy.
Founders & leadership
AB
Akash Bakshi, MScCo-founder & CEO
NM
Nadja Mannowetz, PhDCo-founder & CSO
Investors · 8
Competitors · 3
by search overlapRead on Scientific American31 shared keywordsScientific American is a science and technology news publication covering research, discoveries, and developments across fields such as astronomy, biology, physics, health, and climate. It publishes articles, magazine issues, discussions, and organizes reader travel experiences and editorial features.
Medscape25 shared keywordsMedscape is an online medical information platform providing clinical news, expert perspectives, case studies, quizzes, and reference material across specialties such as cardiology, oncology, neurology, and psychiatry. It serves physicians, nurses, pharmacists, residents, and medical students.
Inverse20 shared keywordsInverse is an online media publication covering entertainment, science fiction, film, television, and pop culture, including reviews, interviews, and news about movies and comic-based franchises. It publishes editorial articles and a daily newsletter for a general audience of genre and entertainment fans.
Companies competing with YourChoice for the same Google search keywords, organic and paid, via search-intersection analysis.
Frequently asked questions
- What does YourChoice do?
- YourChoice Therapeutics is developing YCT-529, a non-hormonal oral contraceptive for men currently in Phase 2 clinical trials. The company targets male contraceptive users seeking alternatives to condoms or vasectomy.
- Who founded YourChoice?
- YourChoice was founded by Akash Bakshi, MSc, Nadja Mannowetz, PhD.
- Who are YourChoice's investors?
- YourChoice's investors include Blue Bear Ventures, Civilization Ventures Management, Llc, Foreground Capital, Future Ventures, North South Ventures, Portfolia, Olive Tree Capital, Refactor Capital.